Corvus Pharmaceuticals unveils updated data from Phase 1/1b trial
Category: #health  By Saipriya Iyer  Date: 2020-02-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Corvus Pharmaceuticals unveils updated data from Phase 1/1b trial

Corvus Pharmaceuticals, Inc., a clinical-stage science driven biopharmaceutical firm focusing on the commercialization and development of precisely targeted oncology therapies along with biomarker patient enrichment selection, has reportedly announced updated results from its Phase 1/1b clinical-stage trial of CPI-818, the ITK inhibitor of the company, presented in an oral presentation during the 12th edition of Annual T-Cell Lymphoma Forum 2020, held in La Jolla, California.

Chief Medical Officer, Corvus, Mehrdad Mobasher, M.D., stated that the Phase 1/1b clinical-stage trial of CPI-818, company’s covalent ITK inhibitor which is designed to address T-cell lymphomas, has been well enrolled and continues to offer promising clinical data for patients suffering from advanced, obstinate forms of this cancer.

Mobasher further stated that till date, the data shows that the pharmacology and biology of ITK inhibition with CPI-818 has been expected and is proceeding according to the plan. The company is thrilled to provide updated data at the T-cell Lymphoma Forum, a meeting specifically devoted to this difficult to treat cancer family. The company is now ready to proceed the trial to higher doses of drug where the company would evaluate the activity in specific disease groups.

The Phase 1/1b trial of CPI-818 study is presently enrolling patients with various types of progressive, refractory T-cell lymphomas, which includes AITL (angioimmunoblastic T-cell lymphoma), PTCL-NOS (peripheral T-cell lymphoma-not otherwise specified), CTCL (cutaneous T-cell lymphoma), as well as other T-cell lymphomas. The study utilizes an adaptive, extended cohort design to evaluate the safety, select the dose, target occupancy, biomarkers, PK (pharmacokinetics), and effectiveness of CPI-818.

The primary phase of the trial has been evaluating increasing doses in successive groups of patients so as to ascertain the optimum dose. The second phase is likely to evaluate tumor and safety response to this ideal dose of CPI-818 in patients with disease specific cohorts that might be extended based on early signs of potency. The study is also enrolling patients at key medical centers located in Australia, South Korea, and the United States.

Source credit: https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-pharmaceuticals-presents-updated-clinical-data-its-phase



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Russia to start clinical trial of novel COVID-19 vaccine in 2 weeks
Russia to start clinical trial of novel COVID-19 vaccine in 2 weeks
By Saipriya Iyer

Russia has recently announced its plan to start the clinical trials of the potential COVID-19 vaccine within a period of two weeks.

The health ministry in Russia has recently inform...

AdaptHealth enters definitive deals to acquire Solara & ActivStyle
AdaptHealth enters definitive deals to acquire Solara & ActivStyle
By Saipriya Iyer

AdaptHealth Corp. has recently entered two separate definitive agreements for the acquisition of Solara Medical Supplies, LLC and ActivStyle, Inc. AdaptHealth is a leading home medical supplies, equipment, and other re...

Ambani’s JioMart unveils a new website to deliver orders across India
Ambani’s JioMart unveils a new website to deliver orders across India
By Saipriya Iyer

Jio Platforms, the top telecom operator along with Jio Retail, which is the top retail chain has recently unveiled JioMart’s new website and has begun taking orders in a large amount from tier 1, tier 2 and metro c...